Inclusion Criteria:  Patients with anterior ST segment elevation acute myocardial infarction undergoing coronary angiography and interventional treatment.*  * Patients with chronic coronary syndrome matched by age, sex and risk factors will also be screened and included as per study design.  Patients with an indication to potent P2Y12 inhibitor therapy (i.e. ticagrelor or prasugrel) for acute myocardial infarction. Population equally amenable to ticagrelor or prasugrel therapy according to the italian drug instruction of use (IFU)  Exclusion Criteria:  Patients with a poor prognosis (less than 12 months) Patients admitted with cardiogenic shock or advanced cardiac failure (NYHA 4) Patients pre-treated before coronary angiography or in chronic therapy with a P2Y12 inhibitor Patients undergoing a medical only approach without percutaneous myocardial revascularization Patients undergoing surgical coronary revascularization Patients with prior history of myocardial infarction or prior coronary revascularization. Patients with contraindications or intolerance to antiplatelet therapy (ticagrelor, prasugrel, clopidogrel or cardioaspirin) Patients scheduled for a treatment with with cangrelor or GPIIb/IIIa inhibitors Patients with active bleeding at the time of inclusion Hemorrhagic diathesis Confirmed history of renal failure with glomerular filtration rate of <30ml/min Severe hepatopathy Patients treated or scheduled for treatment with oral anticoagulant therapy Active cancer or diagnosis any proliferative disease within 5 years. Prior TIA or stroke (ischemic or hemorrhagic) Age >75 years Weight <60kg